Publications by authors named "A E Caccamo"
Since the mid-1990s, scientists have been generating mouse models of Alzheimer's disease to elucidate key mechanisms underlying the onset and progression of the disease and aid in developing potential therapeutic approaches. The first successful mouse model of Alzheimer's disease was reported in 1995 with the generation of the PDAPP mice, which were obtained by the overexpression of gene coding for the amyloid precursor protein (APP). Since then, scientists have used different approaches to develop other APP overexpression mice, mice overexpressing tau, or a combination of them.
View Article and Find Full Text PDFPhage display is widely used in biomedical research. One of the great advantages of phage display is the specificity of the connection of a foreign peptide exposed outside the capsid to the intended target. Secondary detection systems, which are often laborious and costly, are required to identify and quantify the peptide/target interaction.
View Article and Find Full Text PDFWe review the newly classified ascorbate peroxidase-related (APX-R) proteins, which do not use ascorbate as electron donor to scavenge HO. We summarize recent discoveries on the function and the characterization of the APX-R protein of the green unicellular alga and the land plant . Additionally, we conduct analyses on the conserved MxxM motif, present in most of the APX-R protein in different organisms, which is proposed to bind copper.
View Article and Find Full Text PDFArticle Synopsis
- Alzheimer's disease (AD) is a progressive brain disorder leading to memory loss, cognitive decline, and behavioral changes, with few effective treatments currently available.
- Gene therapy is gaining attention as a potential targeted treatment for AD, showing promise in both clinical and preclinical studies.
- Although challenges exist, advancements in research and technology are improving the prospects of gene therapy as a personalized approach to treating Alzheimer's.
Background: Sigma-1 receptors are highly expressed in brain areas related to cognitive function and are a promising target for anti-amnesic treatments. We previously showed that activation of sigma-1 receptors by the selective agonist compound methyl(1 R,2 S/1 S,2 R)-2-[4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl) cyclopropane carboxylate [(±)-PPCC] promotes a remarkable recovery in rat models of memory loss associated to cholinergic dysfunction.
Objective: In this study, we sought to assess the role of (±)-PPCC on working memory deficits caused by noradrenergic depletion.